for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Fresenius SE & Co KGaA

FREG.DE

Latest Trade

44.00EUR

Change

-1.83(-3.99%)

Volume

5,011,365

Today's Range

43.05

 - 

44.88

52 Week Range

40.45

 - 

52.82

As of on the XETRA ∙ Minimum 15 minute delay

Pricing

Previous Close
45.83
Open
44.87
Volume
5,011,365
3M AVG Volume
29.05
Today's High
44.88
Today's Low
43.05
52 Week High
52.82
52 Week Low
40.45
Shares Out (MIL)
557.20
Market Cap (MIL)
25,544.78
Forward P/E
--
Dividend (Yield %)
1.83

Next Event

Fresenius SE & Co KGaA at Morgan Stanley European MedTech & Services Conference

Latest Developments

More

Fresenius CEO Says Biggest Exposure From Coronavirus On Unit Kabi

Fresenius Q4 EBIT Slightly Above Estimates At EUR 1.29 Bln

Fresenius: Fresenius Helios Buys First Hospital In Bogotá, Colombia

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Fresenius SE & Co KGaA

Fresenius SE & Co KGaA is a Germany-based healthcare group. It operates through four business segments. Fresenius Medical Care runs a global network of dialysis clinics, providing treatment for patients with chronic kidney failure. It also offers dialyzers, dialysis machines and renal pharmaceuticals. Fresenius Kabi specializes in intravenously administered generic drugs (IV drugs), clinical nutrition and infusion therapies. It also supplies hospitals with medical devices and products of transfusion technology. Fresenius Helios is a private hospital operator, with over 130 facilities in Germany, including maximum care hospitals and rehabilitation centers and, through Quironsalud, over 80 hospitals and outpatient centers, as well as approximately 300 Occupational Risk Prevention Centers in Spain. Fresenius Vamed manages projects and provides services for health care facilities worldwide, from development and turnkey construction to maintenance and total operational management.

Contact Info

Else-Kroener-Str. 1

+49.6172.6080

https://www.fresenius.de/

Executive Leadership

Gerd Krick

Independent Chairman of the Supervisory Board

Stephan Sturm

Chairman of the Management Board, Chief Executive Officer

Michael Diekmann

Independent Deputy Chairman of the Supervisory Board

Niko Stumpfoegger

Independent Deputy Chairman of the Supervisory Board

Dieter Schenk

Deputy Chairman of the Supervisory Board and Lawyer and Tax Consultant

Key Stats

2.12 mean rating - 25 analysts
Sell
Hold
Buy
Revenue (MM, EUR)

2017

33.9K

2018

33.5K

2020(E)

37.4K
EPS (EUR)

2017

3.250

2018

3.630

2019

3.380

2020(E)

3.554
Price To Earnings (TTM)
13.59
Price To Sales (TTM)
0.72
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
4.66
Total Debt To Equity (MRQ)
--
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
--
Return on Equity (TTM)
--

Latest News

Latest News

REFILE-BRIEF-Fresenius: FDA Approves Fresenius Medical Care's Novalung

* US FOOD AND DRUG ADMINISTRATION APPROVES FRESENIUS MEDICAL CARE FOR NOVALUNG FOR THE TREATMENT OF ACUTE LUNG AND CARDIOPULMONARY FAILURE

UPDATE 3-Fresenius forecasts 2020 profit growth driven by drug, dialysis units

* Kabi most exposed to coronavirus, but plays down overall effect

BRIEF-Fresenius CEO Says Biggest Exposure From Coronavirus On Unit Kabi

* CEO SAYS BIGGEST EXPOSURE FROM CORONAVIRUS IS ON FRESENIUS KABI

BRIEF-Fresenius Q4 EBIT Slightly Above Estimates At EUR 1.29 Bln

* Q4 REVENUE 9.3 BILLION EUR, UP 6% (VERSUS F'CAST 9.34 BILLION EUR)

Fresenius forecasts 2020 sales growth driven by drug, dialysis units

German healthcare group Fresenius forecast 2020 revenue growth on Thursday, saying growth of its infusion drugs unit in emerging markets partially offset softer development in North America in the fourth quarter and noting strong growth of its dialysis business.

BRIEF-Fresenius: Fresenius Helios Buys First Hospital In Bogotá, Colombia

* ACQUIRES FIRST HOSPITAL IN BOGOTÁ, CONTINUING EXPANSION IN COLOMBIA'S PRIVATE HOSPITAL MARKET

Fresenius beats third-quarter forecasts with strong sales of home dialysis treatments

German healthcare group Fresenius <FREG.DE> beat third-quarter revenue forecasts on Tuesday, citing a solid performance by its infusion drugs unit in emerging markets and strong growth in home treatment at its separately listed dialysis business.

Fresenius reports Q3 beat thanks to Kabi growth in emerging markets

German healthcare group Fresenius beat third-quarter revenue forecasts on Tuesday as softer revenue growth in North America was offset by growth of its infusions drugs unit Kabi in emerging markets.

Fresenius drops possible sale of blood transfusion unit - spokesman

German health care group Fresenius has abandoned plans to sell its blood transfusion business, a spokesman said on Sunday, confirming a German media report.

Fresenius' Helios division acquires two hospitals in Colombia

German healthcare group Fresenius <FREG.DE> said on Tuesday its hospitals division Helios had acquired two hospitals in Colombia for 50 million euros ($55.72 million) as the group strengthens its presence outside of Europe.

UPDATE 4-Fresenius slides as weakness in dialysis unit offsets improved outlook

* Fresenius expects FY 4%-7% revenue growth at constant currency

Fresenius raises full-year outlook after Q2 meets expectations

German healthcare group Fresenius raised full-year revenue targets on Tuesday as its adjusted second-quarter sales came in a touch above analysts' expectations.

Fresenius says tighter EU rules could trigger antibiotic shortage

German drugmaker Fresenius warned that stricter production norms being considered by Europe's drug regulator could compound shortages of a life-saving antibiotic that is used by about 25 million patients globally each year.

Fresenius CEO: Don't see us making any large acquisitions this year

German healthcare group Fresenius probably will not make any large acquisitions this year, the group's chief executive officer said on Friday, adding that this was more likely from next year.

Fresenius talking to potential suitors about sale of blood transfusion business - sources

Fresenius has approached potential suitors about the sale of its blood transfusion business, two people with knowledge of the matter said on Friday.

Fresenius talking to potential suitors about sale of blood transfusion business - sources

Fresenius has approached potential suitors about the sale of its blood transfusion business, two people with knowledge of the matter said on Friday.

UPDATE 2-Fresenius makes solid start to year after turbulent 2018

* Confirms full-year guidance (Adds analysts, shares, details)

Fresenius makes solid start to Q1 after troubled 2018

Fresenius reported a quarter of solid sales and earnings growth on Thursday helped by its generic infusion drugs and dialysis units and signs of stabilisation at its troubled German hospital business.

Fresenius may not be ideal owner for some business activities: CEO

German healthcare group Fresenius is happy with its current portfolio but may consider selling some non-core business activities within its units, its chief executive told an association of business journalists on Wednesday evening.

UPDATE 2-Fresenius flags faster earnings growth from 2020 after investment

* Announces 1 bln euros share buyback at Fresenius Medical Care

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up